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ABSTRACT 
We have cloned and sequenced the aroA gene of Pasteurella haemolytica serotype (ST) 2, 
the principal etiologic agent of pneumonic pasteurellosis of sheep. The aroA gene is 1,296 
nucleotides long, has a %G+C content of 42%, and encodes a polypeptide of 432 amino 
acids. The P. haemolytica ST 2 AroA protein has a deduced molecular weight of 47,070 
daltons and an isoelectric point of 4.88. In addition, we have constructed an aroA mutant of 
P. haemolytica ST 2 and demonstrated its diminished ability to grow in Wessman defined 
media lacking the amino acid tryptophan. Previous studies utilizing avirulent aroA mutants 
of the Pasteurella spp. have shown promise as live attenuated vaccine candidates in cattle. 
We hope to use this mutant in future research as a vaccine candidate against pneumonic 
pasteurellosis in sheep. Furthermore, incorporation of this mutant as part of a multivalent 
vaccine containing aroA mutants of P. haemolytica A 1 and P. multocida A3 as well as 
Haemophilus somnus may be desirable for increased control of pasteurellosis in cattle. 
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GENERAL INTRODUCTION 
Hypothesis and Rational 
Pasteurella haemolytica is a prominent pathogen of ruminant species such as cattle and 
sheep (25, 98). It is estimated that the loss to the North American cattle industry due to this 
pathogen is between $750 million to $4 billion annually (98, 71 ). In the United States, 
Bighorn Sheep are the latest to succumb to both the pneumonic and septicemic forms of 
pasteurellosis (98). In the United Kingdom, pasteurellosis of sheep is also a serious economic 
problem (39). Moreover, due to the questionable efficacy of current vaccination programs, 
this disease still poses a threat to the cattle and sheep industries (34, 39). 
Pasteurella haemolytica serotype (ST) 2 is the predominant etiologic agent of pneumonic 
pasteurellosis oflambs and sheep (39). It is a commensal of the upper respiratory tract and 
tonsils of both sheep and cattle ( 10, 34, 98). During periods of stress, bacterial or viral 
infection, climate changes, and seasonal changes, outbreaks of pasteurellosis are often 
observed (10, 34, 39, 98). The spread of Pasteurella through a flock of sheep is not always 
uniform and researchers are not sure as to the primary mechanism of pathogenesis or 
infectious spread. In cattle, however, the speculation is that aerosolized particles from P. 
haemolytica ST 1 infected calves are inspired by neighboring calves (34). In animals 
experiencing stress, the pathogen proliferates on upper respiratory tract mucosa! surfaces 
(34). Colonization of these mucosa! surfaces by P. haemolytica results in no adverse clinical 
effects except transient fever, but is presumed to be a necessary precursor to the development 
of pneumonia. 
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The use of live attenuated pathogens as vaccines has been well studied. In the 1950s, 
Bacon demonstrated attenuation of Salmonella typhi by disruption of the aromatic amino acid 
biosynthetic pathway (6). During infection, the S. typhi mutant exhibited a diminished ability 
to grow yet remained immunogenic (6, 12, 21 , 27, 44-46, 71, 92, 93). Further studies yielded 
information about the aromatic amino acid biosynthetic pathway of which the aroA gene 
product, 5-enolpyruvylshikimate 3-phosphate synthase is a critical enzyme. This pathway 
yields the amino acids tryptophan, tyrosine, and phenylalanine as well as folate, vitamin K, 
and 2,3-dihydroxybenzoate (38, 101 ). Many studies have utilized aroA mutants as avirulent 
attenuated live vaccine candidates. For example, pathogens such as Salmonella typhimurium 
( 46), Salmonella enteritidis (27), Shigellaflexneri (93), Yersinia enterocolitica (12), Yersinia 
pestis (70), Neisseria gonorrhoeae (21), Pasteurella multocida (44), and Pasteurella 
haemolytica ST 1 ( 45) were shown to be attenuated when the aroA gene was mutated. 
Moreover, further experiments have demonstrated that they were good live vaccine 
candidates. Based on these examples, the goal of this study was to clone, sequence and 
construct an aroA mutant of P. haemolytica ST 2 for use as an attenuated live vaccine 
candidate to protect against pneumonic pasteurellosis in sheep. 
Thesis Organization 
This thesis is organized in a standard format consisting of four chapters, a General 
Introduction with Literature Review, Materials and Methods, Results and Discussion and 
Conclusions. This thesis follows the convention of the American Society for Microbiology. 
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Literature Review 
In the early days of bacteriology the only criteria for classifying bacteria were their 
microscopic and cultural morphological features and the circumstances, loyalties or 
personalities associated with their first recognition. 
- K. Zinneman, 1980 
General history 
The history of Pasteurella spp. is vast. Much of the early classification of this group of 
bacteria was based on three criteria: the animal that was infected, biochemical reactions and 
serological reactions (33, 76). The latter two were often contradictory therefore, on many 
occasions the names or classifications of Pasteurella spp. were changed to fit new, emerging 
criteria and ideology (33, 76). 
As early as the 1600s, before the advanced techniques of bacterial isolation and 
identification had been developed, Androvandus of Italy had reported an epizootic disease of 
fowls that proved to be deadly. This seems to be the earliest report of what was later called 
fowl cholera (76). In the 1880s, Toussaint was the first to isolate and describe P. multocida 
from blood, cultivate it in neutralized urine and prove that it was the causative agent of fowl 
cholera (76). 
It was, however, Louis Pasteur who isolated and cultivated P. multocida in pure cultures 
using chicken broth in the 1880s (76). He studied the many aspects of this organism and was 
able to show that an attenuated form of the bacteria protected chickens from subsequent 
infections with the parental strain. From his work came three important biological principles: 
1) recovery from infection would protect against subsequent challenge, 2) attenuation of the 
organism would affect virulence, and 3) immunity would be overwhelmed by a large 
challenge dose ( 17, 52). 
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Pasteurellosis of sheep was first described in 1923 by Spray where he reported a non-
septicemic form of pneumonia in lambs at slaughter (33). Upon examination of diseased 
lamb lungs varying areas of consolidation or hepatization were observed. Furthermore Spray 
isolated Pasteurella-like organisms associated with the pneumonic lesions and demonstrated 
a narrow ring of partial hemolysis on culture. In 1931, Dungal reported an outbreak of 
pneumonia in housed sheep. He reproduced the disease by inoculating healthy sheep 
intratracheally with cultivated organisms collected from infected sheep (39). Although there 
is skepticism based on his description of the causal organism, there seems to be little doubt 
that Dungal was describing P. haemolytica (39). The first observation that clinical symptoms 
may be induced by stress was described in 1938 by Montgomerie et al. (39). They noticed 
that rapid environmental changes such as climate precipitated outbreaks of pneumonia in 
sheep. In 1955 the septicemic form of the disease was first described in the South of 
Scottland by Stamp et al. (39). There they reported a rapidly fatal disease of lambs and 
found the causitive agent to be P. haemolytica. 
Taxonomy of the family Pasteurellaceae 
The family Pasteurellaceae includes a wide variety of Gram negative, facultatively 
anaerobic, chemoorganotrophic, and fermentative bacteria (67). Table 1 lists some common 
features of the family Pasteurellaceae (67). Based on phenotypic and genetic analysis, 
approximately twenty different species of Pasteurella have been identified (25). The 
Pasteurella spp. are differentiated on the basis of beta hemolysis, growth on MacConkey's 
agar, indole production, urease activity, gas from carbohydrates, acid production from lactose 
or mannitol, and 2-dimensional protein electrophoresis (19, 69, 100). However, due to the 
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Table 1. Some common features of the family Pasteurellaceae 
Small Gram-negative rods or coccobacilli 
Facultatively anaerobic or microaerophilic 
Growth temperature 
Motility 
Spores 
Oxidase and/or alkaline phosphatase 
Glucose catabolism (0-F test) 
Nitrate reduction 
Simmons' citrate (growth) 
Arginine dihydrolase 
Adonitol 
L-Sorbose 
*Exceptions: H.aegyptius, H. ducrey i 
30°C-40°C 
+ 
F* 
+ 
Adapted from: Mutters, R. , Mannheim, W., Bisgaard, M., 1989. Taxonomy of the group, In: C. Adlam and 
J.M. Rutter (Editors), Pasteurella and Pasteurellosis. Academic Press, London, pp. 3-34. 
problems inherent with classifying genera based on phenotypic properties alone, i.e. , 
incomplete expression of the genome, techniques such as DNA/DNA hybridization (66) and 
rRNA analysis (28) are used to help establish taxonomic relationships. 
Pasteurella haemolytica was first described in 1921 by Jones and referred to as 
Pasteurella boviseptica group I by Lingieres in his zoological classification of the 
Pasteurella spp. (33). However, as identification of infectious organisms improved, it 
became clear that the classification of bovine and ovine isolates of the family 
Pasteurellaceae into one species, P. boviseptica, was not sufficient. Lingieres thought that 
the family should be broken up into host specific groups such as P. avicida (fowl), P. 
boviseptica (cattle), P suiseptica (swine), and P. oviseptica (ovine) (66, 67). Furthermore, in 
1932, Newsome and Cross separated P. haemolytica from P. multocida giving rise to the two 
independent species of the Pasteurellae (52, 66, 67). 
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The taxonomy of the Pasteurellaceae has undergone several modifications as 
classification techniques have become more precise based on new technologies. Through the 
use of techniques such as capsular antigen typing and DNA/DNA hybridization many of the 
members of this vast family of organisms have been reclassified or eliminated. For example, 
a new classification scheme has excluded several traditional species from P. sensu stricto 
including P. haemolytica, and rRNA evidence has even brought into question their 
classification as Pasteurella (25, 28). Table 2 illustrates the taxa eliminated from the family 
Pasteurellaceae as of 1989 (67). 
Table 2. Taxa eliminated from the family Pasteurellaceae 
Previous designation New description or location 
Haemophilus equigenitalis Taylorella equigenitalis 
rRNA superfamily III 
H. piscium Genus Aeromonas 
H. vagina/is Gardnerella vagina/is 
Morazella (Pasteurella) anatipestifer Flavobacterium/Cytophaga group 
Pasteurella-like Bovine-
lymphangitis group 
P. piscicida 
Pasteurella-like CDC group EF-4 
Enterobacteriaceae 
Vibrionaceae 
rRNA superfamily III 
Criteria used 
Phenotype 
Ribosomal cistrons 
Phenotype 
Phenotype 
DNA binding 
Ribosomal cistrons 
Ribosomal cistrons 
Ribosomal cistrons 
Adapted from : Mutters, R. , Mannheim, W., Bisgaard, M., 1989. Taxonomy of the group, In: C. Adlam and 
J.M. Rutter (Editors), Pasteurella and Pasteurellosis. Academic Press, London, pp. 3-34 
Currently, Pasteurella haemolytica is classified under the family Pasteurella Pohl 1981 
on the basis of genetic relatedness to the other members of this family as determined by DNA 
renaturation (67). This family consists of what's known as the HAP complex of organisms 
which are the genera Haemophilus, Actinobacillus, and Pasteurella. These organisms 
encompass a wide tropism of hosts but share genetic, phenotypic, and to some extent, 
7 
pathologic similarities. For example, hosts of the HAP complex include most mammals such 
as man, cattle, sheep, pigs, dogs, rats, mice, and various birds including chickens and pigeons 
(67). Moreover, the pathology can be pneumonic or septicemic with preference for mucosal 
surfaces (67). A thorough review of the HAP complex is beyond the scope of this paper. 
Therefore, the reader is referred to reference 67 for an in-depth discussion of the genera 
Haemophilus and Actinobacillus. 
Pasteurella haemolytica 
P. haemolytica has been divided into two groups based on fermentation of the sugars 
trehalose and arabinose. The former comprise the T biotypes whereas the latter comprise the 
A biotypes. Recently, however, a move has been made toward reclassifying the T biotypes 
into a separate species, P. trehalosi (25). P. haemolytica can be further typed according to 
capsular antigens. Sixteen serotypes ( 12 are biotype A and 4 are biotype T) have been 
distinguished by indirect hemagglutination developed by Biberstein (4, 34) or rapid plate 
agglutination developed by Frank (34, 36). Biotype A consists of serotypes 1, 2, 5, 6, 7, 8, 9, 
11, 12, 13, 14, and 16. Biotype T includes serotypes 3, 4, 10, and 15 (34). Moreover, many 
strains fall into an 'untypable' category. Indirect hemagglutination of these untypable strains 
fails, presumably due to a lack of soluble antigen. They can be subgrouped by the rapid plate 
agglutination procedure, however (34). The disease produced by the A biotypes and the T 
biotypes are markedly different, and only the A biotypes are the causitive agents of the 
pneumonic form of the disease. 
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Pasteurellosis: the disease 
P. haemolytica and P. multocida are the most prominent pathogens in domestic animals 
causing severe diseases and major economic losses to the cattle, swine, sheep and poultry 
industries. It has been estimated that the cost to the North American cattle industry ranges 
from $750 million to $4 billion annually (71, 98). Recently, P. haemolytica has been 
identified in the Rocky Mountain bighorn sheep population resulting in a loss of bighorn 
sheep due to the pneumonic and septicemic forms of pasteurellosis (98). Moreover, 
Pasteurella is not an isolated problem to North America. As recently as 1991, Bloch 
conducted a serosurvey on 1,474 small ruminants in four districts of Niger (11). Of eight 
diseases studied, pasteurellosis was found to be the main health problem ( 11 ). Therefore, 
efforts to control the progression and propagation of pasteurellosis have been of importance 
to researchers. A full understanding of the pathology of these organisms and their host 
preference is critical to a successful eradication program. 
Pasteurella haemolytica is a member of the HAP complex of pathogens, which infect a 
wide variety of hosts. Many of the diseases produced by these organisms are associated with 
the upper respiratory tract (URT) or the lower genital tract (LGT) (73). The HAP complex of 
diseases are characterized by (i) the clinical symptoms manifested, (ii) the host infected, (iii) 
and the serogroup and/or serotype isolated from the site of infection (99). Diseases produced 
by the HAP complex have been placed into three categories based on clinical symptoms: 1) 
Pneumonia/septicemia which include: hemorrhagic septicemia of cattle, P. multocida; fowl 
cholera of turkeys, water fowl, etc., P. multocida; septicemic pasteurellosis of lambs and 
goats, P. haemolytica; pasteurellosis of rabbits, P. multocida; shipping fever of cattle, P. 
haemolytica, P. multocida, H somnus; enzootic pneumonia of sheep, P. haemolytica. 2) 
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Upper respiratory infections which include: infectious coryza, conjunctivitis, sinusitis of 
chickens and other fowl, H. (para)gallinarum; atrophic rhinitus of swine, P. multocida; and 
conjunctivitis of humans, Haemophilus spp. 3) Local/traumatic infections which include: 
Infected bite wounds of humans and carnivores, P. multocida, P. dagmatis, P. stomatis, P. 
canis; serosal empyemas (e.g. pyothorax) of cats and dogs, P. multocida and others; 
periodontal disease of humans, Actinobacillus actinomycetecomitans; subcutaneous 
granulomas of cattle, P. granulomatis; and cervicovaginitis of cattle, H. somnus (73). This 
list illustrates the wide range of hosts the HAP complex infects and underscores a common 
attraction for mucosa! surfaces. 
Pasteurella spp. survive as commensals on the mucus membranes of the URT and LGT 
of healthy animals. P. haemolytica ST2, and to a lesser extent STl , can be recovered from 
healthy cattle, however, in calves that show clinical manifestations of pneumonic 
pasteurellosis, STl is almost exclusively recovered from the lung (34, 39). Sheep shed and 
succumb to a number of serotypes of P. haemolytica, although serotype 2 is most often 
recovered from pneumonic lung (10, 34, 39, 67). In cattle and sheep, clinical infection with 
P. haemolytica is commonly characterized as an acute, fulminating, fibrinonecrotic 
pleuropneumonic infection of the respiratory tract most frequently associated with "shipping 
fever" (34). The stress associated with the movement of cattle to feedlots allows Pasteurellae 
to proliferate in the URT by an unknown mechanism and spread to the lower respiratory tract 
(LRT) where colonization of the lung occurs. Much focus has been spent on elucidating the 
mechanism of passage of P. haemolytica from the URT to the LRT where clinical pneumonia 
results ( 41 ). The diagram in Figure 1 shows the steps involved in infection of a host by 
members of the HAP complex (81). 
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Predisposing Factors: 
stress, transport, virus, Mycoplasma 
-!. 
Decrease mucociliary clearance, 
impaired alveolar macrophage function 
-!. 
Proliferation and inhalation 
of nasopharyngeal Pasteurellae, 
colonization of the lung 
-!. 
Release of toxins, other virulence factors 
-!. 
Mast cell degranulation, complement activation, 
infiltration and lysis of neutrophils and macrophages; 
-!. 
Fibrinous or purulent pneumonia 
Figure 1. Flow chart of the steps of pasteurellosis infection. 
It has been hypothesized that several factors may be involved in mucosa! colonization of 
P. haemolytica including fimbriae, P. haemolytica AI serotype-specific agglutination antigen 
(PHA 1 SSA), polysaccharide capsule (glycocalyx), lipopolysaccharide (LPS), neuraminidase 
and glycoprotease. Some of these factors directly associate with host cell membranes 
whereas others modify the microenvironment to promote proliferation of the pathogen. P. 
haemoly tica colonizes the lung and evades the host immune response by secreting enzymes 
and toxins (discussed below). Moreover, capsule, capsular antigens, cytotoxins and 
lipopolysaccharides prevent the host immune system from mounting an effective attack 
against the invading pathogen. For example, the capsule is biologically inert, and therefore, 
has a low affinity for opsonization and fixation of immune modulators to the bacterial cell 
membrane, e.g. nonspecific antibody and C3b of the complement cascade respectively. 
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To more fully understand the disease progression of P. haemolytica and to develop 
strategies to eliminate this pathogen, knowledge of its virulence factors and metabolic 
pathways are required. For example, it is understood that the Pasteurellae share many of 
their virulence factors. There are exceptions, however, and perhaps these exceptions allow 
for the host specificity found with each species. An example of this idea is demonstrated 
between P. haemolytica and P. multocida. These two organisms present a relatively similar 
mucoid morphology when cultured on blood agar media containing 5% bovine erythrocytes 
(34). However, the clinical disease often described for each species is different; a fibrinous 
disease is usually seen with P. haemolytica where a purulent pneumonia is normally 
associated with P. multocida (34, 77). Both species use the capsular polysaccharide for 
protection against the host immune response, while each species produces different toxins, 
i.e. leukotoxin and dermonecrotic toxin, respectively, that aid in tissue damage (34, 77). 
Therefore, a better understanding of the immunogens of P. haemolytica and elucidation of 
mechanisms involved in mucosal colonization and destruction of host tissues may aid in the 
design of vaccines to protect cattle and sheep from clinical infection with this pathogen. 
Immunogens of Pasteurella haemolytica 
Prokaryotes have evolved mechanisms that allow them to survive in specific hosts. For 
example, facultative gram negative bacteria like Salmonella, Brucella and Mycobacterium 
have developed the ability to survive intracellularly in macrophages and neutrophils after 
release from the phagolysosomal vacuole (100). Other gram negative bacteria, for example 
Escherichia coli, can survive through mimicry of host proteins on their cell surface or 
antigenic shift of cell membrane proteins ( 100). Still others, such as members of the family 
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Pasteurellaceae, produce toxins that can kill host tissues or immune cells ( 4, 10, 34 ). Many 
pathogenic bacteria utilize a combination of these factors in order to aid their survival within 
the host. The virulence factors associated with P. haemoly tica that may play a role in 
pathogenesis are the adhesins, capsule (glycocalyx), LPS, cytotoxin (exotoxin), and secreted 
enzymes such as neuraminidase or glycoprotease. The list is not comprehensive, but it 
includes some of the more important virulence factors that contribute to colonization and 
pathogenesis of the respiratory tract. 
Adhesins 
Adhesins are cell associated moieties or appendages that facilitate attachment to host cells 
via a cell surface receptor interaction (26). This interaction is important in establishing 
colonization and allowing microcolony formation. These attached colonies resist host 
clearance mechanisms such as the mucociliary escalator, and gain a valuable advantage over 
the host defenses. This advantage may be one of the key points in the pathogenesis of P. 
haemolytica in the ruminant respiratory tract (26). The most common adhesins of 
prokaryotes are fimbriae or pili which are small filamentous appendages on the surface of 
bacterial cells. Their role in infection is thought to be one of adherence to mucosa! surfaces 
in the initial stages of infection (62). In addition to fimbriae however, Gram negative 
pathogens express adhesive factors that are often distinct and independent from fimbriae or 
pili. For example, Bordatella p ertussis utilizes a filamentous hemagglutinin to colonize the 
upper respiratory tract (72). The main adhesin utilized by Bordatella bronchiseptica is the 
bovine erythrocyte hemagglutinin (72). In both of these examples the presence of fimbriae 
does not appear critical for adhesion to cell surfaces. 
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In the late 1980s, Morck et al. demonstrated capsule and fimbriae were present on P. 
haemolytica isolated from cattle showing clinical signs of pneumonic pasteurellosis ( 64 ). 
Typical P. haemolytica cells were evident with clearly visible radial glycocalyces suggesting 
the presence of fimbriae. Two types of fimbriae were identified, a large 12 nm rigid structure 
and a smaller 5 nm more flexible structure. Furthermore, Potter et al., have reported isolation 
and purification of fimbrial subunits, although several laboratories have failed to repeat these 
findings using the same techniques (74). The presence of fimbriae in P. haemolytica has not 
been investigated fully, nor have their existence been confirmed by other investigators (26). 
The serotype-specific capsular antigen of P. haemolytica Al, PHAlSSA, was cloned and 
described as a fimbrial structural unit by Lo et al. (58). Immunoelectron microscopy studies 
of the cloned PHAlSSA confirmed its cell surface location, but failed to reveal a cellular 
morphology consistent with the presence offimbrial structures (41). The role of PHAlSSA 
in the pathogenesis of P. haemolytica is still uncertain, however, Gonzalez et al. speculate 
that the ST I-specific agglutinating antigen could promote adhesion of the pathogen to host 
tissues through a lectin binding interaction with cell surface molecules ( 41 ). 
Capsule 
The capsule (glycocalyx) of P. haemolytica is composed of polyanionic, acidic, high 
molecular weight, heterogeneous polysaccharides, which are useful in serotyping ( 49). 
Encapsulated strains are thought to be more pathogenic, although the presence of a capsule 
does not always correlate with virulence (68). Non-encapsulated isogenic mutants of other 
species are generally avirulent and are quickly removed from the host ( 49). Bacterial capsule 
has been purified and found to be both biologically inert and poorly immunogenic ( 49). 
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Purified capsule behaves immunologically like a hapten, and has been shown to interfere 
with phagocytosis and complement-mediated bacteriolysis (I 0, 20, 25 , 49). Serum resistance 
may be due to the capsule's ability to evade complement fixation by C3b by either the 
alternate or the classical pathways (49). P. haemolytica STl and Haemophilus influenza type 
B are good examples of evading complement lysis (10, 49). However, specific immune 
serum is bactericidal through either of the complement pathways. In contrast, Actinobacillus 
pleuropneumonia ST 5, a member of the HAP complex of organisms, is completely resistant 
to cell lysis in the presence of capsule-specific antibody and complement ( 49). Furthermore, 
an isogenic nonencapsulated mutant of A. pleuropneumonia ST 5 is susceptible to killing by 
complement alone thereby demonstrating that the capsule forms an important barrier between 
the pathogen and the host immune response ( 10, 49). Inzana hypothesized that encapsulation 
interferes with C3b fixation of the cellular membrane, thereby thwarting the early stages of 
the membrane attack complex ( 49). Although the cascade is activated, the capsule prevents 
the membrane attack complex from forming on the cellular membrane, thereby rendering the 
organism resistant to complement. 
P. haemolytica is resistant to phagocytosis in normal serum, and therefore is not cleared 
from the bloodstream or tissues of the host (10, 25, 75). Phagocytosis is thought to occur via 
a receptor mediated pathway whereby C3b or antibody opsonize the bacterium and receptors 
for C3b or the Fe region of the antibody allow recognition of the opsonized complex by the 
macrophage (I 0, 51, 75). Therefore, Pasteurellae which are able to evade opsonization tend 
to evade phagocytosis by alveolar macrophages and neutrophils. In addition to evading host 
immune responses, Morck has shown that P. haemolytica uses it's capsule to attach to 
alveolar epithelium (15, 64). Some reports have shown that fimbriae may act to support this 
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adhesion and therefore resist clearance by alveolar macrophages, however the mechanism by 
which this occurs is not fully understood. Furthermore the existence of fimbriae is still under 
much debate thereby making elucidation of the mechanism of adhesion of Pasteurellae more 
difficult to study. 
Lipopolysaccharide 
Lipopolysaccharide produced by Pasteurella spp. is similar to LPS of other gram 
negative bacteria (49). It is composed oflipid A, a core oligosaccharide, and an antigenic 
polysaccharide chain referred to as 0 antigen ( 49). LPS has been studied extensively in 
Pasteurellae and other organisms. Its chemical composition has been determined and its role 
in pathogenicity is briefly summarized below. 
P. haemolytica LPS is intimately associated with the capsule and capsular antigens. 
Hence, purification of LPS has been difficult. Nevertheless, LPS has been shown to be 
associated with immune protection of animals; the extent of the immune reaction depends on 
the animal species inoculated, LPS-type (either S or R types), route of inoculation and 
method of inoculation (96). Purified LPS has been determined to be antigenic and is found to 
be of the R-type. Pirosky isolated LPS-protein complexes and demonstrated that they were 
immunogenic and toxic (73). However, rabbit antiserum against the LPS antigen was shown 
to weakly protect mice after challenge with LPS (22). Conversely, in some avian strains of 
Pasteurella anti-LPS antibody seems to be of importance in immunity (25, 78). Therefore, 
the efficacy of anti-LPS antibody against pasteurellosis is still somewhat unresolved. 
The effects of endotoxin occur through a two-fold mechanism (26, 49). During the first 
hour of exposure to LPS, a neutrophil independent event occurs whereby pulmonary 
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hypertension is observed without increased vascular permeability. This response is primarily 
due to increased plasma cyclooxygenase-dependent arachidonic acid metabolites, especially 
thromboxane A2 and prostaglandin F 2. In addition, cAMP levels in plasma elevate to a peak 
in 1 hour and cGMP elevate more slowly to a maximum at 12 hour. Emau et al. have 
suggested that the effects of endotoxin at the cellular level are mediated by the cyclic 
nucleotides (29, 30). The second phase of LPS toxicity occurs within an hour and is 
neutrophil dependent. Neutrophils infiltrate the lung, and cause an increase in vascular 
permeability due to secretion of mediators, e.g. leukotrienes, oxygen radicals, and proteolytic 
enzymes. Slocombe et al. (85) and Breider et al. ( 13) have found that neutrophils play an 
important role in the development of the severe lesions of bovine pneumonic pasteurellosis, 
especially fibrinous exudation and thrombosis. 
LPS delivered by bronchoscopy to sheep lung led to a variety of clinical and pathological 
effects ( 16). A marked decline in circulating leukocytes was followed by mild leukocytosis. 
An increase in neutrophils was noted, and LPS evoked local inflammation, edema, 
hyperemia and hemorrhage in the lung ( 16, 85). The response to LPS in that experiment was 
comparable to acute pneumonia elicited by live P. haemolytica. 
There is evidence that LPS toxicity may be enhanced by complexing with lung surfactant 
(15, 85). Brogden et al. found that after incubation ofLPS with surfactant, surfactant vesicles 
formed and stabilized the LPS. This complex was significantly more dense than surfactant 
alone ( 15). They found that toxicity in mice with the complex was greatly enhanced over 
LPS alone. Goto and Rylander noted the same results using E. coli LPS (4). 
~ - --- -· ---- -----
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Cytotoxins 
Many pathogenic bacteria make use of cytotoxins that target substrates found on the host 
cells to inactivate host cell defenses. The classic example is that of the RTX toxin 
a-hemolysin (HlyA) produced by the non-hemorrhagic strains of E. coli and the 
enterohemorrhagic toxin (EhxA) produced by hemorrhagic strains of E. coli ( 4, 7). The HlyA 
and EhxA toxins associate with the target cell and disrupt cellular membranes by forming 
pores and thereby lyse the cell (7). Similarly, leukotoxin, produced by P. haemoly tica 
disrupts cell membrane structures ultimately lysing the cell. 
Classically, two exotoxins have been associated with P. haemoly tica , hemolysin, which 
gave rise to the P. haemoly tica species name, and leukotoxin. However, recently, Murphy et 
al. constructed a leukotoxin mutant by allelic exchange and demonstrated typical ~-hemolytic 
activity on sheep and rabbit blood agar was abolished. Similar results were confirmed in our 
lab and therefore suggest that hemolysin and leukotoxin are one in the same (65). 
Leukotoxin (LKT) has received much attention due to its ability to destroy cells involved 
with adherence and immunity. In the late 1970s and early 1980s studies of P. haemoly tica 
culture supernatants or washed cells demonstrated toxicity for bovine alveolar macrophages 
(8, 60). These studies yielded evidence that LKT was involved in the destruction of 
macrophages and neutrophils, and lent credence to the thesis that much of the pathological 
cellular damage of the host was due to destruction of host granulocytes. Hence, isolation, 
identification and elucidation of the role ofLKT on the pathogenesis of P. haemolytica have 
been investigated extensively. 
Leukotoxin is produced by all known serotypes of P. haemolytica (25) with the exception 
of four untypable strains (4). LKT, a RTX toxin, shares a high degree of homology to the 
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E.coli a-hemolysin at the nucleotide level (4). Researchers have postulated that LKT plays a 
role in virulence by causing cytolysis of alveolar macrophages and neutrophils. Furthermore, 
LKT induces platelet destruction and release of fibrinogen and vasoactive compounds as 
additive affects in the infected lung lesion (25). It has been suggested that LKT has a duel 
action dependent on concentration of the toxin in the microenvironment and the cells present 
( 4, 86). That is, ruminant leukocytes exposed to low levels of LKT have reduced phagocytic 
and oxygen radical generation capabilities. Conversely, high levels of LKT lyse leukocytes 
and platelets (25, 86). In an attempt to explain the activation-inhibition paradox, Steven and 
Czuprynski determined that cell death was in part mediated by apoptosis (86). They noted 
marked cytoplasmic membrane blebbing (zeiosis) and chromatin condensation and 
margination, the hallmarks of apoptosis. In another study, however, LKT effects on bovine 
neutrophils included ruptured membranes, numerous vesicles within the cytoplasm and 
pyknotic nuclei, all hallmarks of necrosis (4). These studies, however, are not universally 
accepted, though they do demonstrate the detrimental effects of LKT on bovine leukocytes 
and may, in part, explain the contrast between commensal or pathogenic P. haemolytica. 
Leukotoxin has shown specificity for ruminant leukocytes whereas nonruminant 
leukocytes and other cell types such as kidney cells, fibroblasts , and endothelium are 
resistant (25, 83). This specificity may define the different forms of pneumonia associated 
with P. haemolytica and P. multocida. In the former, a fibrinous pneumonia is most often 
described whereas the latter usually produces a purulent pneumonia (34). This striking 
difference may be attributed to the production of dermonecrotic toxin (DMT) by P. 
multocida that seems to have affinity for porcine osteoclasts (32). The DMT has little if any 
effect on ruminant leukocytes whereas LKT will lyse them (32). It has been postulated that 
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the release of toxic intermediates and inflammatory mediators from lysed and activated 
leukocytes contributes to the cellular damage and inflammation in the lung resulting in a 
fibrinous pneumonia (25, 34). Analysis of the lung shows focal arrays of cellular damage 
where toxic intermediates have killed host tissue (34). 
Characterization of LKT at the molecular level has revealed that the toxin is a protein with 
a molecular mass of 105 kDa. Purified leukotoxin has an isoelectric point between 4.1 and 
4.6 and retains activity at pH 4.5 through pH 9 (4). The gene coding for LKT, !kt, has been 
cloned and sequenced (23, 56, 57). More recently, studies have focused on the !kt operon and 
construction of !kt mutants to further investigate the role of LKT in disease (43). The !kt 
operon has the typical RTX family genetic arrangement. It is comprised of four genes 
designated lktC-lktA-lktB-lktD, where the lktC gene product, 19.9 kDa, is required for 
activation of the proleukotoxin to the mature leukotoxin by posttranslational acylation of the 
LKT peptide (7, 31). The lktA gene encodes the structural toxin and lktB, 79.6 kDa, and lktD, 
54.7 kDa, genes are associated with exportation of the mature toxin to the extracellular 
environment (9). 
Previous studies have correlated high serum antibody responses to LKT with resistance to 
experimental challenge of cattle (37). Furthermore, recent studies by Lainson et al. confirmed 
that LKT was immunogenic when a lktA:lacZ fusion reacted with a strongly neutralizing 
monoclonal antibody localized to a 32 amino-acid region near the C-terminus of the 
leukotoxin A molecule (53). These studies provide the knowledge needed to construct LKT 
mutants targeting operon sequences other than the lktA gene sequences. Based on these 
studies, one can speculate that mutants designed to retain immunogenicity while abolishing 
toxicity may be of great advantage. 
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Secreted enzymes 
Prokaryotic organisms under harsh conditions have developed modalities of survival that 
involve the production of enzymes that can be secreted into the microenvironment to 
neutralize deleterious molecules present on the host cell surface (47, 87, 88, 90, 94). Some of 
these enzymes target cell surfaces and cleave acidic residues to make the microenvironment 
more habitable. Neuraminidase and glycoprotease (generally referred to as sialidases) cleave 
N-linked and 0-linked sialoglycoconjugates, respectively, into free sialic acid residues (63). 
Pathogens such as Vibrio cholera (94), Bacteroidesfragilis (47), Salmonella typhimurium 
L T2 ( 4 7), P. haemolytica (87, 90), and P. multocida (88) contain sialidases. These organisms 
also contain genes that allow them to ingest and metabolize the released sialic acid residues 
(47, 87, 88, 90, 94, 95). Other organisms such as E. coli don't contain sialidase genes, but 
they may contain systems for uptake and degradation of scavenged free sialic acid residues 
(95). In this fashion host cell surface defenses are used to propagate the invading pathogen by 
neutralizing their protective capacity. Gottschalk demonstrated this phenomenon by 
removing the sialic acid from salivary glycoproteins and noted their reduced protective affect 
against pathogens ( 42). In these cases the pathogen strips away the sialic acid and allows 
attachment and formation of microcolonies (89). 
The first report of Pasteurella spp. producing neuraminidase was by Scharmann et al. in 
1970 (80). In that report, 3 of 5 strains of P. haemolytica and 102 of 104 strains of P. 
multocida were shown to produce neuraminidase. In 1981 Frank and Tabatabai examined P. 
haemolytica and found that biotype A serotypes 1, 5, 6, 7, 9, and 12 and no biotype T strains 
produced neuraminidase (35). However, a later report by Straus et al. demonstrated that all 
serotypes except serotype 11 of P. haemolytica biotype A produced neuraminidase (87). 
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These neuraminidases were characterized with neutralizing antibody from P. haemoly tica 
Al , by substrate specificity, and by molecular weight and found they were similar. 
The role neuraminidase may play in the virulence of P. haemoly tica in vivo is still unclear. 
In vivo production of anti-neuraminidase antibodies occurs during experimental infection 
with P. haemoly tica suggesting that neuraminidase is induced during infection, and based on 
previous reports, one may hypothesize that neuraminidase may play a role in mucosa! 
colonization and survival of the pathogen (82, 84, 89, 48). Presponse1m, a vaccine developed 
in the late 1980s by Shewen and colleagues, utilized the soluble antigens; leukotoxin, a 
serotype-specific outer membrane protein, neuraminidase, and sialoglycoprotease harvested 
during logarithmic phase of P. haemoly tica (82, 84) to protect cattle against P. haemoly tica 
ST 1. They demonstrated in both field and laboratory trials that Presponse1m was effective in 
preventing disease in cattle (54, 82, 84). 
Otulakowski was the first to describe the glycoprotease of P. haemoly tica in the early 
1980s ( 4 ). He demonstrated the formation of a protease specific for sialoglycoproteins of 
human erythrocytes and cytotoxic for bovine pulmonary macrophages. In 1990 Abdullah et 
al. showed that glycoprotease was found in culture supematants of P. haemoly tica ST 1, 2, 5, 
6, 7, 8, 9, and 12 by degradation of glycophorin A (1). However, no activity was found in ST 
3, 4, 10, and 11. In 1991 the same group reported they had cloned the P. haemolytica STl 
glycoprotease gene and expressed it in E.coli (2). Furthermore, in 1992 they characterized the 
enzyme and reported it as a neutral metalloprotease that specifically cleaves 0-linked 
sialoglycoconjugates, in effect confirming the work of Otulakowski (3). Lee et al. 
demonstrated that in vivo production of glycoprotease results in antiglycoprotease antibody 
production in calves suggesting the presence of the enzyme during pathogenesis of P. 
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haemolytica ( 54 ). The role of this enzyme seems to parallel that of neuraminidase, but 
relatively little work has been done to conclusively demonstrate this point (63) 
The role of secreted enzymes has not been clearly shown in the pathogenesis of P. 
haemolytica. However, work toward producing mutant P. haemolytica STl devoid of 
neuraminidase or glycoprotease is underway and may provide the evidence needed to link 
these enzymes to virulence (91 ). 
Vaccination 
Vaccination has been an important strategy in controlling the incidence of pasteurellosis. 
Multiple types of vaccines have been used to vaccinate cattle and sheep against P. 
haemolytica including subunit vaccines, bacterins, supernatant fractions, and live attenuated 
vaccines strains (2, 5, 18, 22, 24, 25, 34, 39, 40, 45, 49, 50). Commercial multicomponent 
vaccines are currently available utilizing antigens from P. haemolytica biotypes T3, T4, TIO, 
and T 15 that are involved in the septicemic form of pasteurellosis ( 50). However, few 
effective vaccination protocols are currently available to protect sheep against pneumonic 
pasteurellosis, and those that are available show marginal efficacy (34). Several cattle 
vaccines are available which confer moderate protection, but these are ineffective in sheep 
due to serotype specificity and a lack of cross protection (34). 
As of 1989, inactivated bacterial preparations, bacterial extracts and some live 
preparations have been used as vaccines in cattle and sheep without much success (34, 39). 
For example, Rodger et al. used aparainfluenza 3 (PB) virus attenuated live vaccine 
(originally licensed for use in cattle) to vaccinate sheep intranasally based on the premise that 
PB is a predisposing factor to pasteurellosis in cattle (79). Ewes that seroconverted to PB 
23 
were either immune to the disease or showed reduced incidence of pasteurellosis (79). 
However, this study also demonstrated that this vaccine protected sheep from pneumonic 
pasteurellosis temporarily, for one season. 
Vaccine failures have led to increased interest in the role of mucosa! immunity in 
protection. Early experiments by Wells in the late 1970s using sodium salicylate extracts of 
P. haernolytica Al to immunize sheep followed by inoculation with PB virus (to predispose 
the animals to disease) showed that animals that were challenged 7 days after vaccination 
with P. haernolytica Al succumbed to infection (96). This led Wells to conclude that 
humoral immunity was not sufficient to provide protection. He speculated that cell-mediated 
immunity must play a key role in protection against pneumonic pasteurellosis (96). In a 
separate study, however, passive transfer of purified and nonpurified convalescent serum 
from either conventionally reared sheep that presented with pneumonia or experimentally-
infected sheep immunized with a P. haernolytica A2 vaccine to specific pathogen free lambs, 
protected 94-100% of the animals (50). The authors concluded that humoral immunity was 
sufficient to prevent pasteurellosis. This apparent contradiction illustrates the complexity 
associated with assessing immunological resistance to pneumonic pasteurellosis. 
Vaccination studies continued, however, despite the lack of understanding of mucosa! 
immunity. For example, Chandrasekaran compared an oil adjuvant vaccine consisting of 
locally isolated P. haernolytica ST 7 and P. rnultocida serotypes A and D from infected sheep 
to the commercially available Carovax vaccine (Wellcome Laboratories) in imported cross-
bred lambs (22). Although the oil adjuvant vaccine reduced lung lesions as compared to 
controls when P. haernolytica was used for challenge, lambs challenged with both P. 
haernolytica and P. rnultocida were not protected from pneumonic lesions. Carovax was also 
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found to be ineffective at reducing lesions in lambs infected with both Pasteurellae (22, 30). 
In another study, a sodium salicylate extract of P. haemolytica ST2 grown in iron replete 
media to induce the expression of iron regulated proteins was used to vaccinate specific 
pathogen free lambs ( 40). In this study some protection was conferred to SPF lambs after 
aerosol challenge with P. haemolytica A2. Another example is the vaccine Presponsetm 
developed by Shewen and colleagues in the late 1980s. It is comprised of soluble antigens 
evolved from logarithmic growth phase P. haemolytica STI and both field and laboratory 
trials have shown promise in protection against pneumonic pasteurellosis in cattle (54, 82, 
84). 
These vaccines are all examples of either bacterins or supematants used to elicit protective 
antibodies in the immunized animals. A number of live vaccines of P. haemolytica have been 
used and none required transformation of the bacterium. However, current technologies now 
allow genetic manipulation of P. haemolytica to be possible, and for the first time yield site 
directed mutants for the purpose of vaccine development. However, work to refine and 
evolve bacterins, extracts with new adjuvants, etc. is ongoing, and as yet, efficacy in the field 
has not met with expectations of the user. Therefore rationally attenuated live vaccines have 
become more desirable. 
The use of rationally attenuated live vaccines in the control of pasteurellosis in cattle and 
sheep is a relatively new field (91 ). Construction of live attenuated vaccines has become 
feasible since the genes involved in restriction-modification of exogenous DNA have been 
characterized ( 14). Construction of attenuated mutant strains may prove to be better vaccine 
candidates then their predecessors. Previous studies by Collins et al. noted that live vaccines 
appear to protect better than bacterins because they elicit a stronger cell-mediated immune 
25 
response (24 ). In addition, humoral immunity is enhanced in live preparations due to the 
induction of genes during in vivo growth (92). Therefore, with the stronger immunity elicited 
by live vaccines, attenuated live P. haemoly tica may prove to be of great importance in 
controlling pneumonic pasteurellosis (24, 92). 
With these arguments in mind, our aim in this study was to develop a rationally attenuated 
strain of P. haemoly tica ST 2 for use as a live vaccine candidate. Previous studies have 
demonstrated that the attenuation of virulent organisms through mutation of the aroA gene 
has produced effective auxotrophic mutant strains (6, 12, 21 , 27, 44-46, 70, 93, 101). 
Use of auxotrophic aroA mutants as attenuated live vaccines 
The aromatic amino acids phenylalanine, tyrosine and tryptophan are essential for growth 
of all known life forms. Elucidation of the biosynthetic pathway(s) of each of the aromatic 
amino acids has been reported (38, 101 ). Moreover, the pathways consist of an elegantly 
arranged cascade of reactions containing molecules that converge into a branch point reaction 
whereby all of the aromatic amino acids are derived. Elimination of the precursor reactions, 
therefore, truncates the pathway and the organism cannot synthesize these amino acids. 
Figure 2 shows the pathway(s) involved and the common intermediates required for the 
synthesis of the aromatic amino acids (101). Briefly, glucose is catabolized to phosphoenol 
pyruvate and erythrose 4-phosphate through the glycolysis pathway (38). These two 
molecules then proceed through a common "shikimate" pathway to yield chorismate (38). 
Chorismate is know as a "common branchpoint" molecule from which all three aromatic 
amino acids are synthesized as well as folate, vitamin K, ubiquinone, and 2,3-
dihydroxybenzoate (38). The enzyme 5-enolpyruvylshikimate 3-phosphate synthase (aroA) 
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Figure 2. Biosynthetic pathway of the amino acids tyrosine, phenylalanine, and tryptophan. 
(Biochemistry third edition, Zubay, 1993) The enzyme 5-enolpyruvylshikimate 3-phosphate 
synthatse (aroA) catalizes the reaction that converts shikimate 3-phosphate to 5-
enolpyruvylshikimate 3-phosphate. Mutation of the aroA gene blocks this pathway thereby 
starving the organism of these essential amino acids. 
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is responsible for catalyzing the reaction that converts shikimate 3-phosphate to 5-
enolpyruvylshikimate 3-phosphate. The product is a precursor to the common branchpoint 
molecule chorismate from which all three aromatic amino acids are derived. Mutation in the 
aroA gene eliminates the precursors necessary for biosynthesis of all three amino acids 
thereby creating an auxotrophic mutant phenotype that relies on exogenous aromatic amino 
acids for proper protein synthesis. Mutants of this nature should lack the ability to survive in 
vivo for long periods of time, therefore making them good vaccine candidates. Organisms 
mutated in the aroA gene locus have been well characterized in the literature for use as 
rationally attenuated live vaccines (6, 12, 21, 27, 44-46, 70, 93, 101). 
In 1950, Bacon et al. were the first to demonstrate attenuation of Salmonella typhi after 
mutation in the aromatic amino acid biosynthetic pathway (6). Subsequent efforts with 
pathogens such as Salmonella typhimurium (46), S. enteritidis (27), Shigellaflexneri (93), 
Yersinia enterocolitica (12), Y pestis (70), Neisseria gonorrhea (21), Pasteurella multocida 
(44), and P. haemolytica ST 1 (45, 92) have produced additional aroA mutants as vaccines 
candidates. 
Mutants of the aromatic amino acid family have shown some promise in Pasteurella spp. 
Homphampa et al. observed that a live aroA P. multocida mutant completely protected mice 
that were immunized intraperitoneally twice and subsequently challenged with the parental 
strain ( 44 ). Two years later the same researchers demonstrated the efficacy of an aroA 
mutant of P. haemolytica STl in mice that were immunized intraperitoneally twice and 
subsequently challenged with a lethal dose of the parental strain ( 45). Moreover, Adlar 
recently demonstrated attenuation after observing a 6-log increase in infectious dose 50 in 
mice exposed to aroA P. multocida ST 1 and 3 mutants (5). Furthermore, virulence was 
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restored by complementation of the mutant with a copy of wild type aroA in trans. These 
studies provide evidence that supports the contention that inactivation of the aroA gene 
effectively attenuates Pasteurella spp. and may be a useful means to produce an effective 
live vaccine in sheep against P. haemolytica A2. 
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MATERIALS AND METHODS 
Bacterial strains and growth 
Luria broth (LB) and 2xYT were prepared as described (59). Columbia broth and 
Columbia agar were prepared according to the manufacturer's directions (Difeo, Detroit, 
Mich.). Wessman defined media (97) lacks the amino acid tryptophan, therefore, organisms 
harboring a mutation in the aromatic amino acid biosynthetic pathway cannot grow on this 
media. A protocol is supplied in Appendix A. Ampicillin ( 10 µg per ml) and kanamycin ( 50 
µg per ml) were used for selection with P. haemolytica NADC-Dl53 STl and NADC-Dl 71 
ST2. For E. coli strains, ampicillin (100 µg per ml), kanamycin (50 µg per ml), and 
tetracycline (35 µg per ml) were used for appropriate selection. All strains were grown at 
37°C unless otherwise stated. A summary of the bacterial strains and plasmids appears in 
Table 3. 
Cloning of the P. haemolytica serotype 2 aroA gene 
Polymerase chain reaction (PCR) primers (Integrated DNA Technologies [IDT], 
Corralville, la.) were designed based on the STl aroA DNA sequence (92) and used to 
amplify the ST 2 aroA from P. haemolytica NADC-D 171. A logarithmic phase P. 
haemolytica culture grown in Columbia broth at 37°C for 3 h with shaking were used as the 
template source. The forward primer, 5'-TATGAGGCATTACTGCGTGAAGG-3', 
designated D 171#1 hybridized to nucleotides 1 through 23 of the minus strand, the reverse 
primer, 5'-AGCGGTTGGGCTTAGTCTGCCAC-3', designated Dl 71#2 hybridized to the 
plus strand at nucleotides 1534 through 1556. PCR was carried out on a thermocycler 
(Perkin-Elmer 9600 Thermocycler, Perkin-Elmer Inc., Branchburg, N.J.) according to the 
Table 3. Bacterial strains and plasmids used in this study 
Strain or plasmid 
Strains 
E.coli 
AB2829 
DHlOB 
PhalMtase 
P. haemolytica 
NADC-Dl53 
NADC-D171 
Plasmids 
pSK 
pD70 
pD80 
pPharoA 1 
pPharoA2 
pPharoA3 
pPharoA 3.1 
pPCRIIaroA 
pPhAmpr 
Characteristics 
K-12 strain harboring a mutation in the aroA gene 
Standard cloning strain used in this study 
Recombinant DHlOB harboring the mPhal methyltransferase gene 
Serotype 1, plasmidless 
Serotype 2, plasmidless 
Cloning vector (Ampr) 
3.5 kb plasmid encoding Kanr 
4.2 kb plasmid encoding Ampr 
3.2 kb HindIII clone of P. haemolytica aroA (pSK) 
2.2kb HindIII-Cla I digested pPharoA 1 aroA fragment (pSK) 
Same fragment as pPharoA 2 cloned on pBC SK 
200 hp Nde 1-BstEII deletion of aroA from pPharoA 3 
Serotype 2 aroA PCR product cloned onto pPCRII TA cloning vector 
2.2 kb Sau 3AI fragment of p080 cloned onto pBC SK 
Source or reference 
92 
Gibco-BRL 
14,92 
NADCa (R. Briggs) 
NADC (R. Briggs) 
Stratagene 
NADC (R. Briggs) 
NADC (R.Briggs) 
92 
92 
92 
This study 
This study 
92 
pPharoA -ampr pPharoA 3.1 with Ampr gene from pPhAmpr cloned into the Nde 1-Bst Ell site This study 
pBB l 92C Broadhost range temperature sensitive This study 
pBB 192C~aroA-ampr Bss HI ~aroA-ampr cassette from pPharoA-ampr cloned on pBB 192C This study 
a NADC, National Animal Disease Center, Ames, Iowa. 
VJ 
....... 
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manufacturer's directions in a total volume of 50 µl with 1 µl of cells using the ampliTaq 
Gold system (Perkin-Elmer). The cycle program was as follows: 10 seconds at 95°C; 1 
minute at 95°C; 2 minutes at 55°C; 3 minutes at 72°C; 7 minutes at 72°C; hold at 4°C. Steps 
2-4 were cycled 30 times. 
The ST 2 aroA PCR product was ligated into the pPCRII TA cloning vector (Invitrogen 
Inc, San Diego, Calif.) using T4 DNA ligase (Bethesda Research Laboratories [BRL], 
Gaithersburg, Md.). The ligation mix was diluted 1: 10 in sterile dH20 and used to transform 
electrocompetent E. coli DH-1 OB (BRL) cells (Gene Pulser, Bio-Rad Laboratories, 
Richmond, Calif.). Cells were recovered for 1 hat 37°C in 1 ml of SOC broth (2% Bacto-
Tryptone, 0.5% Bacto Yeast Extract, 8 mM NaCl, 2.5 mM KCl, 10 mM MgCb, and 20 mM 
glucose) and then spread onto B-Agar plates (1 % Bacto-Tryptone, 0.8% NaCl, 2% Difeo 
agar, 10 µg per ml thiamine) containing 0.002% 5-bromo-4-chloro-3-indolyl-P-D-
galactopyranoside (X-Gal), 100 µM isopropyl-P-D-thiogalactopyranoside (IPTG) and 
ampicillin and grown overnight at 3 7°C. 
Seven white colonies were picked and each was grown in 2 ml of 2x YT (59) broth 
containing ampicillin. Double stranded plasmid DNA was prepared by a standard alkaline 
lysis method (59). Plasmid DNA was digested with EcoRl (Bethesda Research Laboratories), 
and electrophoresed on a 1 % agarose gel (data not shown). One isolate containing a 1.5 kb 
insert was chosen for further study was designated pPCRIIaroA. 
Nucleotide sequencing of the P. haemolytica serotype 2 aroA gene 
Fourteen primers were designed and synthesized (IDT) utilizing the ST 1 aroA published 
sequence for both the plus and minus strands (92). Cesium chloride purified (59) double 
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stranded pPCRIIaroA plasmid was used as template for sequencing reactions (Iowa State 
University Nucleic Acid Facility, Ames, IA.), and the nucleotide sequence (Automated 
Sequencer ABI Prism Model 377 Version 3.0 ABI200 Version 2.1.1.) of aroA was 
determined (MacDnasis Pro, Hitachi Software Ltd., San Bruno, Calif. and Mac Vector, 
Kodak Co., New Haven, Conn.) for both strands. 
Plasmid and P. haemolytica serotype 2 aroA mutant constructions 
To construct an aroA mutant of P. haemolytica ST2, we used an existing replacement 
plasmid containing the P. haemolytica ST 1 aroA as described by Tatum et al. (92) . Briefly, 
the ST 1 aroA was cloned in the following way. A 1.3 kb PCR amplified E. coli aroA 
fragment was used to probe Hindlll digested P. haemolytica STl genomic DNA revealing a 
3.2 kb band. Hindlll digested P. haemolytica ST 1 genomic DNA was then fractionated by 
agarose gel electrophoresis, and the 3.0 kb-3.4 kb fragments were isolated and cloned into 
Hindlll digested alkaline phosphatase-treated pBlueskript SK cloning vector (Stratagene, La 
Jolla, Calif.). The resulting plasmid was designated pPharoA 1. Functional aroA was 
confirmed by complementation of an aroA- strain of E.coli K-12, AB2829. Restriction 
enzyme analysis of pPharoA 1 revealed that an insert of 3.2 kb had been cloned. Another 
plasmid, pPharoA2, was constructed by excision of an internal 2.2 kb Clal-Hindlll aroA 
fragment from pPharoA 1 and cloned into the Accl-Hindlll site of pBluescript SK. To permit 
engineering of a replacement plasmid, the 2.2 kb Clal-Hindlll aroA fragment was ligated 
into the Accl-Hindlll site of pBC SK (Stratagene). This plasmid was designated pPharoA3. 
In order to construct a vector for allelic exchange, the aroA gene in pPharoA3 was 
disrupted by inserting a gel-purified ampicillin resistance cassette from the plasmid pPhampR 
(92) into a unique Ndel site of aroA. The resulting plasmid, pPharoA-arnpr was amplified in 
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E. coli DH 1 OB PhaIMtase harboring the mPhal methylase gene to protect the DNA against 
Phal cleavage (14). P. haemoly tica ST1-NADC-D l 53 and ST2-NADC-Dl 71 were prepared 
for electroporation by the following protocol. A 25 ml Columbia broth culture was incubated 
for 3 hat 37°C, the cells were centrifuged at 5,000 x g for 15 min, washed twice in 25 ml of 
272 mM sucrose at 0°C and resuspended in 272 mM sucrose to an equal volume of pelleted 
cells. One to five micrograms of DNA were introduced into 100 µl of competent P. 
haemolytica by electroporation (Gene Pulser, Bio-Rad) using 0.1 cm cuvettes (Bio-Rad) at 
15 KV/cm, 800 n and 25 µF. Time constants ranged from 9.0 to 10.5 ms. Additional controls 
consisted of an endogenous P. haemoly tica plasmid from the NADC-D80 strain, pD80, 
bearing an ampicillin resistance cassette as the positive control, and a no DNA control. Cells 
were recovered in 1 ml of Columbia broth on ice for 10 min and then transferred to 3 7°C for 
3 h with shaking. After 3 h, 10 Columbia agar plates containing ampicillin were spread with 
100 µl of transformed cells and incubated overnight at 37°C. The positive and negative 
controls were plated on Columbia agar containing ampicillin. Since no ampicillin resistant 
P. haemolytica ST2 were recovered after several efforts with pPharoA-ampr, it was desirable 
to construct and utilize a non-suicidal replacement plasmid. 
A deletion plasmid was constructed using the aroA gene from pPharoA3 and a novel 
plasmid, pBB l 92C. Plasmid pBB l 92C contains a temperature sensitive origin of replication 
cloned from an endogenous plasmid of P. haemolytica ST1-NADC-D70, pD70, a kanamycin 
(kan) resistance cassette from the transposon Tn903 (ClonTech, Palo Alto, Calif), and the 
ColEI origin ofreplication for amplification in E. coli (unpublished data). A 200 bp deletion 
was created in the aroA gene of pPharoA3 by double digestion with Ndel and BstEII 
restriction endonucleases. The resultant ends were filled in using deoxynucleoside 
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triphosphates and the Kienow fragment of E. coli polymerase I. A 2.2 kb P-lactamase gene 
was isolated from plasmid pPhAmpr (92) by double digestion using the restriction 
endonucleases HindIII and Xbal. The resultant ends were filled in as described above and the 
fragments was separated on a 1 % agarose gel and purified using a spin column (Supelco 5-
5600A GenElute Agarose Spin Column, Supelco Inc, Bellefonte, Pa.). The purified P-
lactamase gene was mixed with the pPharoA3 vector and ligated with T4 DNA ligase. The 
resulting plasmid was designated pPharoA3.l. 
The ~aroA-ampr fragment was excised from pPharoA3.l by digestion with BssHI and 
cloned into the Eco RI site of pBB l 92C after filling the ends to make each fragment blunt. 
The resultant replacement plasmid, pBB192C~aroA-ampr, was methylated by passage 
through E. coli PhaIMtase as described above. Approximately 1 µg of methylated 
pBB 192~aroA -ampr was used to transform P. haemolytica STl-NADC-D 153 and P. 
haemolytica ST2-NADC-D 171 as described above. Electroporated cells were transferred to 1 
ml of cold Columbia broth and incubated at 4°C for 10 min. The cells were then recovered at 
the permissive temperature of 30°C for 1 h. After recovery, the cells were spread onto 
Columbia agar plates containing kanamycin and incubated 24 h at 30°C. 
Six kanamycin resistant colonies were grown in 5 ml Columbia broth containing 
kanamycin overnight at 30°C with shaking. To ensure that the P. haemolytica isolates 
contained the replacement plasmid and to determine that the plasmid did not rearrange, 
double stranded plasmid DNA was extracted by a standard alkaline lysis method (59), 
digested with EcoRI restriction endonuclease and separated on a 1 % agarose gel. One isolate 
containing plasmid DNA consistent with pBB192C~aroA-ampr was chosen for further work. 
36 
In order to select for recombinant P. haemolytica, cells containing pBB l 92~aroA-ampr 
were incubated at the nonpermissive temperature of 40°C on Columbia agar containing 
ampicillin. Resultant colonies were passed to 2 ml of Columbia broth containing ampicill in 
and incubated overnight at 40°C to confirm ampicillin resistance. The cultures were struck 
onto Columbia agar plates without selection and grown overnight at 30°C to ensure the 
single .crossover mutants were cured of plasmid. Individual colonies then were scored for 
ampicillin and kanamycin resistance and tryptophan auxotrophy by inoculation into 96 well 
microtiter plates containing Columbia broth with ampicillin, Columbia broth with 
kanamycin, and Wessman defined media lacking the amino acid tryptophan and grown at 
37°C (97). 
Several isolates were found to be ampicillin and kanamycin resistant and tryptophan 
negative. One such ST 2 isolate designated El 1, was chosen for further study. To generate 
the desired aroA mutant via excision of the replacement plasmid from the chromosome, El 1 
was passed at 40°C in 2 ml Columbia broth with ampicillin selection for 5 h. Resultant 
growth was inoculated into 200 ml of Columbia broth without selection and incubated 
overnight at 30°C. After passage the culture was struck for isolation onto Columbia agar 
without antibiotic and incubated overnight at 40°C. Resultant colonies were patched onto 
Columbia agar containing ampicillin and replica-patched onto Columbia agar containing 
kanamycin and were grown at 37°C overnight. Colonies which were both ampicillin resistant 
and kanamycin sensitive were passed in 2 ml Columbia broth containing ampicillin and 
incubated at 37°C overnight to confirm antibiotic resistance. Four colonies confirmed the 
appropriate antibiotic phenotype were inoculated into 2 ml of Wessman broth. All failed to 
grow in the defined media. 
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Southern blots were performed on the putative aroA mutants to determine if double 
crossover mutant were generated. Chromosomal DNAs were obtained from all 4 putative 
double crossover mutants in the following way. Cell were grown overnight in 25 ml 
Columbia broth containing ampicillin at 37°C. The cells were pelleted by centrifugation for 
15 min at 5,000 x g, resuspended in lysis buffer (1 % sodium dodecyl sulfate (SDS), 15 mM 
EDTA, 60 mM Tris-HCl pH 7.5, 50 mM NaCl), and incubated for 30 min at room 
temperature. The resultant DNA was extracted 3 times with an equal volume of chloroform 
and precipitated with 2 volumes 95% ethanol. The DNA was pelleted by centrifugation for 
15 min at 10,000 x g and washed in cold 70% ethanol. The DNAs were resuspended in 2 ml 
TE buffer, and samples were quantitated spectrophotometrically as described by Maniatis 
(59). 
One microgram of genomic DNA from putative mutant and wild type ST2-NADC-D 171 
were digested with HindIII. Plasmid pBB192C~aroA-ampr was digested with Sspl. The 
DNAs were fractionated on 0.8% agarose gels. The gels were subsequently denatured in 1.0 
M NaCl and 0.5 M NaOH for 30 min, neutralized with 3.0 M NaCl and 1.5 M NaOH for 30 
min, and DNAs were transferred to a nylon membrane (Hybond-N; Amersham Corp., 
Arlington Heights, Ill.) by capillaryphoresis according to the procedure of Maniatis (59). 
Filters were baked for 1 h at 80°C followed by incubation with prehybridization solution 
[5X SSC (IX SSC is 0.15 M NaCl and 0.015 M sodium citrate), 5X Denhardt's solution (59), 
0.1 % SDS, 10 µg per ml sonicated salmon sperm DNA, and 50% formamide] at 42°C for 30 
min. The prehybridization solution was removed and replaced with hybridization solution 
(prehybridization solution without Denhardt's solution) containing 107 cpm of 32P-labeled 
probe. Probes were prepared from a gel purified 2.2 kb fragment containing the STl aroA 
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gene or linearized plasmid pBB 192C using a random hexanucleotide radio labeling kit 
(Boehringer Manneheim) and [32a-P]dCTP. Filters were hybridized at 42°C for 18 h and 
washed twice with wash solution (IX SSC and 0.1 % SDS) at 42°C for 15 min and once at 
65°C for 15 min. Membranes were exposed to X-AR (Eastman Kodak Co., Rochester, N.Y.) 
film at -70°C for 2 h. One isolate designated, F9.80, showed genetic characteristics 
consistent with allelic exchange of the host chromosomal aroA gene and the ~aroA-ampr 
replacement cassette as demonstrated when probed with gel-purified radiolabeled aroA. 
Moreover, F9.80 genomic DNA was shown to be devoid of vector sequences when probed 
with radio labeled pBB 192C vector. 
To conclusively demonstrate that F9.80 was an aroA deletion mutant, Southern blot 
analysis was repeated. One microgram of HindlII digested genomic DNA of parental P. 
haemoly tica NADC-Dl 71, P. haemolytica NADC-Dl 71 ~aroA-ampr mutant F9.80, and 15 
ng of StyI digested pBB192C~aroA-ampr linearized plasmid were fractionated on an agarose 
gel as described above. Southern blots were performed as described above and the filters 
were probed with P. haemolytica NADC-D60 (STl) aroA; linearized pBB192C plasmid, and 
the 200 bp NdeI-BstEII fragment from STl aroA respectively. Furthermore, tryptophan 
auxotrophy confirmed that F9.80 was a mutant in the aromatic amino acid biosynthetic 
pathway. Inoculation of the mutant into Columbia broth containing ampicillin, Wessman 
defined media lacking tryptophan, and Wessman defined media containing tryptophan (0.5 
µg per ml) and monitoring growth was performed to demonstrate auxotrophy. 
In addition to the genomic endonuclease restriction pattern observed above, final 
confirmation that F9.80 was P. haemolytica serotype 2 was performed when F9.80 was 
struck onto blood agar plates containing 5% sheep erythrocytes and incubated overnight at 
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37°C for observation of ~-hemolysis (34). In addition, rapid plate agglutination using ST 1 
and ST 2 specific antiserum was performed by mixing a sample of cells harvested from 5 % 
sheep blood agar plates with the specific antisera and observing agglutination (36) to confirm 
the authenticity of the P. haemolytica aroA mutant serotype. 
Nucleotide sequence accession number 
The P. haemolytica ST2 aroA sequence reported here was deposited in Genbank under the 
accession number U89948 and a copy is supplied in Appendix B. 
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RESULTS AND DISCUSSION 
Cloning of the P. haemolytica serotype 2 aroA gene 
Two specific primers corresponding to P. haemolytica STl aroA gene sequences were 
used to synthesize by PCR a 1.5 kb aroA product using P. haemolytica ST 2 genomic DNA 
as template. Previous studies indicate that the nucleotide sequence of aroA, an essential 
housekeeping gene in bacteria, is highly conserved across many genera of prokaryotes (92, 
101). For instance, the aroA gene of P. haemolytica STl shows 75, 70, 69, and 68% identity 
with the aroA gene sequences of P. multocida, Klebsiella pneumonia, Y. enterocolitica, and 
E. coli, respectively (92). Therefore, it appeared likely that the P. haemolytica ST2 aroA 
nucleotide sequence would have a high degree of similarity to the ST 1 aroA nucleotide 
sequence. As expected, the primers amplified a 1.5 kb product from ST2 equal in size to the 
aroA from serotype 1 (data not shown). The PCR product was cloned into PCRII TA to 
generate plasmid pPCRIIaroA (Table 3) and the DNA sequence of the insert was determined. 
Nucleotide sequencing of the P. haemolytica serotype 2 aroA gene 
The P. haemolytica ST2 aroA sequence was obtained using fourteen different primers 
designed from P. haemolytica STl aroA (92). The complete nucleotide sequence of the ST2 
aroA and the deduced amino acid sequence are shown in Figure 3. An open reading frame of 
1,296 nucleotides encoded a 432 amino acid residue polypeptide. Serotype 2 aroA has a 
deduced molecular weight of 47,070 daltons, a %G+C content of 42% and an isoelectric 
point of 4.88. The gene had 99.1 % identity to serotype 1 aroA suggesting a close relationship 
between these serotypes of P. haemolytica. An erratum was detected in the original ST 1 
aroA sequence, discrepancies between STl and ST2 aroA were confirmed by analysis of the 
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* * * * * 
GTGATTGTTCGCTCGATAGCAGGTTATGGAATGCCGAATCATTTACGCATTAGTATCGGTTTACCGCAAGAAAACGAGAG 80 
M 
ATTTTTTACTGCCTTATTGAAAGTGTTAGCTTAACAAGCGGTTACCTTTTATGAAAATTTTACAAATTTAAAGAGAAAAA 160 
E K L T L T P I S R V E G E I N L P G S K S L S N R> 
TGGAAAAACTAACTTTAACCCCGATTTCCCGAGTAGAAGGCGAGATCAATTTACCTGGTTCTAAAAGCCTGTCTAACCGA 240 
A L L L A A L A T G T T Q V T N L L D S D D I R H M L> 
GCCTTATTATTAGCCGCCTTAGCCACCGGTACGACTCAAGTGACCAATTTATTAGATAGTGATGATATTCGACATATGCT 320 
N A L K A L G V K Y E L S D D K T V C V V E G I G G A> 
CAATGCCTTAAAAGCGTTAGGCGTGAAATATGAGCTATCGGACGATAAAACCGTCTGTGTAGTTGAAGGGATTGGTGGAG 400 
F K V Q N G L S L F L G N A G T A M R P L A A A L C> 
CTTTTAAGGTTCAAAACGGCTTATCACTGTTTCTCGGCAATGCAGGCACGGCAATGCGACCACTTGCAGCAGCATTGTGT 480 
L K G A E T A Q I I L T G E P R M K E R P I K H L V D> 
TTAAAAGGGGCGGAAACAGCTCAAATCATTCTTACCGGTGAGCCAAGAATGAAAGAACGCCCGATTAAACATTTAGTCGA 560 
A L R Q V G A E V Q Y L E N E G Y P P L A I S N S G L> 
TGCTTTACGCCAAGTAGGGGCAGAGGTACAGTATTTAGAAAATGAAGGCTATCCGCCGTTAGCAATTAGCAATAGCGGTT 640 
Q G G K V Q I D G S I S S Q F L T A L L M S A P L A> 
TGCAAGGTGGAAAAGTGCAAATTGACGGCTCGATTTCCAGCCAATTTCTAACCGCATTGCTGATGTCTGCCCCATTAGCG 720 
E S D M E I E I I G D L V S K P Y I D I T L S M M N D> 
GAAAGCGATATGGAAATTGAGATTATCGGTGATCTGGTATCAAAACCTTATATTGATATTACCCTTTCGATGATGAACGA 800 
F G I T V E N R D Y K T F L V K G K Q G Y V A P Q G N> 
TTTTGGTATTACGGTTGAAAATCGAGATTACAAAACCTTTTTAGTTAAAGGTAAACAAGGCTATGTTGCTCCACAAGGTA 880 
Y L V E G D A S S A S Y F L A S G A I K G K V K V T> 
ATTATTTGGTGGAGGGAGATGCCTCTTCTGCCTCTTATTTCTTAGCCTCCGGTGCGATTAAAGGCAAGGTAAAAGTAACG 960 
G I G K K S I Q G D R L F A D V L E K M G A K I T W G> 
GGCATTGGTAAAAAATCGATCCAAGGCGACCGCTTGTTTGCCGATGTGTTGGAAAAAATGGGGGCAAAAATCACTTGGGG 1040 
E D F I Q A E Q S P L K G V D M D M N H I P D A A M T> 
AGAGGATTTTATTCAAGCCGAGCAATCCCCGCTAAAAGGCGTAGATATGGATATGAATCATATTCCTGATGCGGCAATGA 1120 
I A T T A L F A E G E T V I R N I Y N W R V K E T D> 
CGATTGCAACAACCGCTTTATTTGCCGAAGGAGAAACAGTTATCCGCAATATTTATAACTGGCGGGTAAAAGAAACCGAC 1200 
R L T A M A T E L R K V G A E V E E G E D F I R I Q P> 
CGCTTGACAGCAATGGCAACCGAATTGCGTAAAGTCGGGGCAGAGGTAGAAGAAGGGGAAGATTTTATTCGGATTCAACC 1280 
L A L E N F Q H A E I E T Y N D H R M A M C F S L I A> 
GCTTGCGTTAGAAAACTTCCAGCACGCTGAAATTGAAACCTATAACGATCACCGTATGGCAATGTGTTTTTCATTAATTG 1360 
L S N T E V T I L D P N C T A K T F P T Y F R E L E> 
CGTTATCGAATACAGAAGTGACGATCTTAGATCCAAATTGTACCGCTAAAACGTTCCCGACTTACTTTAGGGAGTTGGAA 1440 
K L S V R 
AAATTATCGGTCAGATAAAAGTAAAAAAGGATTCAGAAAACTGAATCCTTTTTACGTTTTATTGTGGCAGACTAAGCCCA 1520 
Figure 3. Nucleotide sequence and deduced amino acid sequence of P. haemolytica NADC-
Dl 71 ST2 aroA 
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original sequence autoradiographs of ST 1 aroA and the automated sequence results of ST2 
aroA. Corrections were made to the STl aroA sequence where the autoradiograph of both the 
plus and minus strands agreed, and a homology comparison of the ST2 aroA to ST 1 aroA 
was based on corrected sequence (Figure 4). 
Previous studies by Tatum et al. demonstrated that P. haemolytica ST 1 aroA, like P. 
multocida, was transcribed by its own promoter (44, 92). These observations were based on 
experiments demonstrating that the cloned aroA was capable of complementing a mutant 
strain of E. coli K-12 AB2829 independent of orientation in the plasmid (92). Furthermore, 
P. haemolytica ST 1 aroA was found to differ in genetic arrangement to other gram negative 
bacteria in which aroA and sere constitute an operon with aroA downstream of the sere 
promoter (92). The sere gene encodes a biosynthetic enzyme leading to the synthesis of the 
non-aromatic amino acid serine. Studies by Lim et al. utilizing a sere-aroA::lacZ 
translational fusion, demonstrated that the E. coli aroA gene product is coordinately 
expressed by the sere promoter in a cAMP dependent manner (55). A comparison of the 
sequences upstream of the P. haemolytica STl aroA gene on plasmid pPharoA2 
demonstrated no homology to sere genes thereby suggesting that aroA and sere do not 
constitute an operon in P. haemolytica. It remains unclear as to why Pasteurella aroA 
possesses its own promoter. Other respiratory pathogens such as Haemophilus influenzae 
contain an aroA under the control of the upstream purN promoter (61 ). In this example, the 
purN (glycinamide ribonucleotide transformylase) stop codon overlaps the start codon of 
aroA suggesting that they may be translationally coupled. These studies indicate a regulation 
of aroA in response to environmental factors aside from synthesis of aromatic amino acids 
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STl aroA GTGATTGTTCGCTCGATAGCAGGTTATGGAATGCCGAATCATTTACGCATTAGTATCGGT 
************************************************************ 
ST2 aroA GTGATTGTTCGCTCGATAGCAGGTTATGGAATGCCGAATCATTTACGCATTAGTATCGGT 
STl aroA TTACCGCAAGAAAACGAGAGATTTTTTACTGCCTTATTGAAAGTGTTAGCTTAACAAGCG 
************************************************************ 
ST2 aroA TTACCGCAAGAAAACGAGAGATTTTTTACTGCCTTATTGAAAGTGTTAGCTTAACAAGCG 
STl aroA GTTACCTTTTATGAAAATTTTACAAATTTAAAGAGAAAAATGGAAAAACTAACTTTAACC 
************************************************************ 
ST2 aroA GTTACCTTTTATGAAAATTTTACAAATTTAAAGAGAAAAATGGAAAAACTAACTTTAACC 
STl aroA CCGATTTCCCGAGTAGAAGGCGAGATCAATTTACCTGGTTCTAAAAGCCTGTCTAACCGA 
************************************************************ 
ST2 aroA CCGATTTCCCGAGTAGAAGGCGAGATCAATTTACCTGGTTCTAAAAGCCTGTCTAACCGA 
STl aroA GCCTTATTATTAGCCGCCTTAGCCACCGGTACGACTCAAGTGACCAATTTATTAGATAGT 
************************************************************ 
ST2 aroA GCCTTATTATTAGCCGCCTTAGCCACCGGTACGACTCAAGTGACCAATTTATTAGATAGT 
STl aroA GATGATATTCGACATATGCTCAATGCCTTAAAAGCGTTAGGCGTGAAATATGAGCTATCG 
************************************************************ 
ST2 aroA GATGATATTCGACATATGCTCAATGCCTTAAAAGCGTTAGGCGTGAAATATGAGCTATCG 
STl aroA GACGATAAAACCGTCTGTGTAGTTGAAGGGATTGGTGGAGCTTTTAAGGTTCAAAACGGC 
************************************************************ 
ST2 aroA GACGATAAAACCGTCTGTGTAGTTGAAGGGATTGGTGGAGCTTTTAAGGTTCAAAACGGC 
STl aroA TTATCACTGTTTCTCGGCAATGCAGGCACGGCAATGCGACCACTTGCAGCAGCATTGTGT 
************************************************************ 
ST2 aroA TTATCACTGTTTCTCGGCAATGCAGGCACGGCAATGCGACCACTTGCAGCAGCATTGTGT 
STl aroA TTAAAAGGTGAGGAAAAATCCCAAATCATTCTTACCGGTGAACCAAGAATGAAAGAACGC 
******** l * l ***** l * l * l ******************** I****************** 
ST2 aroA TTAAAAGGGGCGGAAACAGCTCAAATCATTCTTACCGGTGAGCCAAGAATGAAAGAACGC 
STl aroA CCGATTAAACACTTAGTCGATGCTTTACGCCAAGTAGGGGCAGAGGTACAGTATTTAGAA 
***********!************************************************ 
ST2 aroA CCGATTAAACATTTAGTCGATGCTTTACGCCAAGTAGGGGCAGAGGTACAGTATTTAGAA 
STl aroA AATGAAGGCTATCCACCGTTGGCAATTAGCAATAGCGGTTTGCAGGGCGGAAAAGTGCAA 
**************l***** l ***********************l** I************ 
ST2 aroA AATGAAGGCTATCCGCCGTTAGCAATTAGCAATAGCGGTTTGCAAGGTGGAAAAGTGCAA 
Figure 4. Homology comparison between P. haemolytica NADC-D60 STl and P. 
haemolytica NADC-Dl 71 ST2 aroA. The two genes display a 99.l % identical match. The 
A TG start codon and T AA stop codon are in bold and mismatches are denoted by vertical 
lines. 
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STl aroA ATTGACGGCTCGATTTCCAGCCAATTTCTAACCGCATTGCTGATGTCTGCCCCATTAGCG 
************************************************************ 
ST2 aroA ATTGACGGCTCGATTTCCAGCCAATTTCTAACCGCATTGCTGATGTCTGCCCCATTAGCG 
STl aroA GAAGGCGATATGGAAATTGAGATTATCGGTGATCTGGTATCAAAACCTTATATTGATATT 
*** [******************************************************** 
ST2 aroA GAAAGCGATATGGAAATTGAGATTATCGGTGATCTGGTATCAAAACCTTATATTGATATT 
STl aroA ACCCTTTCGATGATGAACGATTTTGGTATTACGGTTGAAAATCGAGATTACAAAACCTTT 
************************************************************ 
ST2 aroA ACCCTTTCGATGATGAACGATTTTGGTATTACGGTTGAAAATCGAGATTACAAAACCTTT 
STl aroA TTAGTTAAAGGTAAACAAGGCTATGTTGCTCCACAAGGTAATTATTTGGTGGAGGGAGAT 
************************************************************ 
ST2 aroA TTAGTTAAAGGTAAACAAGGCTATGTTGCTCCACAAGGTAATTATTTGGTGGAGGGAGAT 
STl aroA GCCTCTTCTGCCTCTTATTTCTTAGCCTCCGGTGCGATTAAAGGCAAGGTAAAAGTAACG 
************************************************************ 
ST2 aroA GCCTCTTCTGCCTCTTATTTCTTAGCCTCCGGTGCGATTAAAGGCAAGGTAAAAGTAACG 
STl aroA GGCATTGGTAAAAAATCGATCCAAGGCGACCGCTTGTTTGCCGATGTGTTGGAAAAAATG 
************************************************************ 
ST2 aroA GGCATTGGTAAAAAATCGATCCAAGGCGACCGCTTGTTTGCCGATGTGTTGGAAAAAATG 
STl aroA GGGGCAAAAATCACTTGGGGAGAGGATTTTATTCAAGCCGAGCAATCCCCGCTAAAAGGC 
************************************************************ 
ST2 aroA GGGGCAAAAATCACTTGGGGAGAGGATTTTATTCAAGCCGAGCAATCCCCGCTAAAAGGC 
STl aroA GTAGATATGGATATGAATCATATTCCTGATGCGGCAATGACGATTGCAACAACCGCTTTA 
************************************************************ 
ST2 aroA GTAGATATGGATATGAATCATATTCCTGATGCGGCAATGACGATTGCAACAACCGCTTTA 
STl aroA TTTGCCGAAGGAGAAACAGTTATCCGCAATATTTATAACTGGCGGGTAAAAGAAACCGAC 
************************************************************ 
ST2 aroA TTTGCCGAAGGAGAAACAGTTATCCGCAATATTTATAACTGGCGGGTAAAAGAAACCGAC 
STl aroA CGCTTGACAGCAATGGCAACCGAATTGCGTAAAGTCGGGGCAGAGGTAGAAGAAGGGGAA 
************************************************************ 
ST2 aroA CGCTTGACAGCAATGGCAACCGAATTGCGTAAAGTCGGGGCAGAGGTAGAAGAAGGGGAA 
STl aroA GATTTTATTCGGATTCAACCGCTTGCGTTAGAAAACTTCCAGCACGCTGAAATTGAAACC 
************************************************************ 
ST2 aroA GATTTTATTCGGATTCAACCGCTTGCGTTAGAAAACTTCCAGCACGCTGAAATTGAAACC 
STl aroA TATAACGATCACCGTATGGCAATGTGTTTTTCATTAATTGCGTTATCGAATACAGAAGTG 
************************************************************ 
ST2 aroA TATAACGATCACCGTATGGCAATGTGTTTTTCATTAATTGCGTTATCGAATACAGAAGTG 
Figure 4 (continued). 
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STl aroA ACGATCTTAGATCCAAATTGTACCGCTAAAACGTTCCCGACTTACTTTAGGGACTTGGAA 
***************************************************** !****** 
ST2 aroA ACGATCTTAGATCCAAATTGTACCGCTAAAACGTTCCCGACTTACTTTAGGGAGTTGGAA 
STl aroA AAATTATCGGTCAGATAAAAGTAAAAAAGGATTCAGAAAACTGAATCCTTTTTACGTTTT 
************************************************************ 
ST2 aroA AAATTATCGGTCAGATAAAAGTAAAAAAGGATTCAGAAAACTGAATCCTTTTTACGTTTT 
STl aroA ATTGTGGCAGACTAAGCCCAACCGCT 
************************** 
ST2 aroA ATTGTGGCAGACTAAGCCCAACCGCT 
Figure 4 (continued). 
alone. However, regulation of the P. haemoly tica aroA gene remams to be examined. 
Constitutive expression of aroA , however, may explain de nova synthesis of aromatic amino 
acids to support growth of P. haemoly tica on Wessman defined media. 
A homology comparison between P. haemoly tica STl and ST2 aroA revealed 99.l % 
overall sequence identity (Figure 4). Sequences upstream of the structural gene, however, 
were shown to be 100% identical suggesting that ST2 aroA does not constitute an operon 
with serC. 
P. haemolytica mutant construction and characterization 
The purpose of this study was to construct an aroA mutant of P. haemoly tica ST2 and 
demonstrate its attenuation in vitro. Towards that end, several replacement plasmids were 
developed and introduced into P. haemolytica using new technology to protect the exogenous 
DNA from endogenous restriction barriers. Each plasmid developed was considered superior 
to the previous plasmid, which failed to produce an aroA mutant. First, plasmid pPharoA3 
containing the P. haemolytica STl aroA gene disrupted by an ampicillin resistance cassette 
was methylated by passing the plasmid through E. coli containing Pha!Mtase on a cosmid 
and subsequently using the plasmid to transform logarithmic phase P. haemolytica STl and 
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ST2. Despite repeated attempts no transformants were obtained by using up to 5 µg of 
pPharoA3. Positive control pD80 plasmids from E. coli Pha/Mtase transformed with a 
frequency of approximately 6 x 103 transformants per µg supercoiled DNA. These results 
indicated that Co/El-based plasmids do not replicate in NADC-D 171 . The relatively low 
efficiency of transformation with pD80 implies that the larger pPharoA3 may have been 
introduced at levels too low for generating a mutant by allelic exchange (Figure 5). 
Previous studies by Tatum et al. employing a chimeric hybrid plasmid which contained 
both the P. haemolytica pD70 origin of replication (an endogenous plasmid of Pasteurella) 
and the ColEl origin of replication were successful in generating deletion mutations (92). 
This shuttle vector could replicate both in Pasteurella and in E. coli thereby circumventing 
the low transformation frequency observed with the introduction of suicide plasmids into 
Pasteurella while allowing amplification of plasmid in E. coli. After its introduction into P. 
haemoly tica the hybrid plasmid generated single crossover products. The authors found that 
the single crossover products were unstable, presumably due to the plasmid origin of 
replication destabilizing chromosomal replication (92). Since antibiotic selection was 
maintained, the unstable single crossover products would be eliminated if they resolved to 
wild type during passage at 40°C due to loss of the excised hybrid plasmid. Only mutants 
arising by excision of the plasmid to produce a deletion mutant exhibited robust growth 
under antibiotic selection. 
To permit more control over the plasmid system, a temperature sensitive shuttle vector 
was developed utilizing the ColEI origin of replication and a mutagenized P. haemolytica 
origin of replication derived from the streptomycin resistant plasmid pD70. This plasmid, 
BssHI L /,"" ,,f ,7,% 
x 
l 
47 
I pPharoA3 
Digest with Ndel andBstEII and ligate Amp' 
fragment 
BssHI 
, ""' ' ~;; j pPharoA3 I 
l Excise &lroA-ampr cassette by digestion with BssHI, Bhmt, ligate into Eco RI site of pBBl 92C, methylate 
plasmid, electroporate in P haemolytica serotype 2. 
x 
qroA I P haem chromosome 
l Homologous recombination between replacerrent plasmid and chromosome to generate an aroA mutant. 
, , J P haem ST2 mutant 
Figure 5. Construction of an aroA mutant of P. haemolytica NADC-D 171 ST 2. The 
temperature conditional broad host range plasmid pBB l 92C carrying the tlaroA-ampr 
cassette was employed to successfully develop an aroA mutant. 
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pBBI 92C, contained a kanamycin resistance cassette and was approximately 3.5 kb in size. 
In the current study, a deletion was introduced into P. haemolytica aroA and into the deletion 
site a 2.2 kb P. haemolytica ampicillin resistance cassette was inserted. The mutated aroA 
gene containing ampr was cloned into pBB192C giving rise to the plasmid pBBI92C~aroA ­
ampr. This construct was able to overcome problems associated with the suicide vector 
described previously. The steps involved in constructing the replacement plasmid 
pBBI92C~aroA-ampr and generating a gene replacement mutant via allelic exchange are 
depicted in Figure 5. 
Since pBB l 92C separates transformation and recombination steps, it was anticipated that 
transformation of P. haemolytica could be accomplished. Plasmid pBB I 92C~aroA-ampr was 
methylated by passage through E.coli PhaIMtase and used to transform P. haemoly tica STl 
and ST2 by electroporation. Double stranded plasmid DNA was isolated from six kanamycin 
resistant colonies and all plasmid DNAs analyzed by restriction enzyme digestion were 
shown to be pBB I 92C~aroA -ampr. 
Since recombination is a rare event, amplification of a single transformant would result in 
the generation of large numbers of bacteria harboring the replacement plasmid and thus 
increase the likelihood that specific integration of the replacement plasmid into the host 
chromosome would occur. After growth at 30°C, the temperature was shifted to the 
nonpermissive temperature of 40°C or 42°C in ampicillin selection to prevent plasmid 
replication and promote integration of the plasmid into the host chromosome. It was found 
that passage ofNADC-Dl 71 at >40°C resulted in unacceptably short duration of viability. 
Passage at 40°C resulted in acceptable viability and several colonies were selected for further 
study. These colonies, in theory should contain recombination products with integrated 
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plasmids or double crossover mutants, however, our previous experience with P. haemoly tica 
demonstrated that ampicillin selection was weak giving rise to several spontaneously 
resistant colonies on solid media which failed to grow in broth containing ampicillin. 
Therefore, colonies from the plates grown at 40°C were passed in broth containing ampicillin 
and grown at 40°C to collect viable clones. To induce a second recombination event that 
resulted in resolution of the replacement plasmid and to cure the cells of the remaining 
plasmids, the overnight culture was struck for isolation onto Columbia agar plates containing 
no antibiotic and grown at 30°C. Individual colonies were then scored for antibiotic 
resistance and auxotrophy. Construction of the replacement cassette yielded a mutated aroA 
gene in which 200 bp of the N-terminal region of the aroA gene product was deleted. 
Therefore, a single recombination event could produce one of two products based on the site 
of homologous recombination. If the integration of the plasmid resulted from a 
recombination event occurring upstream of the deletion, an inactivated aroA gene would 
result. However, if the integration of the plasmid resulted from a recombination event 
occurring downstream of the deletion, a functional aroA gene would result. Therefore, by 
screening for P. haemolytica mutants unable to support growth in Wessman defined media, 
one would isolate single crossover mutants occurring on the upstream arm of the replacement 
plasmid or products of double crossover events (Figure 6). As expected, several ampicillin 
and kanamycin resistant isolates failed to grow in Wessman defined media. Southern blot 
analysis of Hindlll digested genomic DNAs from these isolates demonstrated the presence of 
integrated plasmid DNA as compared to wild type DNAs when probed with the gel-purified 
2.2 kb aroA gene from pPharoA3 and the plasmid vector pBB 192C (data not shown). The 
isolates yielded two bands of 4 kb and 5.5 kb when probed with aroA sequences whereas 
Kan' 
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Figure 6. Illustration of the events required to yield a single crossover integrant and excision 
of the plasmid to generate a gene replacement mutant. 
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wild type aroA yielded a 3 kb band. Furthermore plasmid sequences were identified in each 
isolate when probed with vector pBB l 92C sequences. These results are consistent with 
integration of the replacement plasmid into the chromosomal aroA gene. No mutants 
resulting from double crossover events were isolated. 
To screen for mutants that have undergone a second crossover event the El 1 isolate, a 
single crossover mutant unable to grow in defined media, was passed at the permissive 
temperature of 30°C for several generations. Growth at this temperature will yield one of two 
events; 1) the plasmid may resolve out of the chromosome yielding a wild type genotype, or 
2) an allelic exchange event may occur yielding a mutated chromosomal aroA gene. 
Furthermore, resolved plasmid is cured from the when the organism is grown without 
antibiotic selection at the permissive temperature. Each passage was struck onto a master 
plate of Columbia agar without antibiotic and grown overnight at 40°C to stabilize remaining 
single crossover integrants and to generate isolated colonies for screening. Isolated colonies 
were scored for ampicillin and kanamycin resistance. 
Four isolates were identified that were ampicillin resistant, kanamycin sensitive, and 
failed to grow in Wessman defined medium. Southern blot analysis of HindIII digested 
genomic DNAs of the four isolates and wild-type NADC-D 171 revealed that three isolates 
contained vector sequences and the ~aroA-ampr cassette when probed with radiolabeled 
pBB l 92C. This was consistent with the molecular profile of a single crossover product (data 
not shown). Also Southern blotting confirmed the presence of the kanamycin resistance gene 
in the chromosome which implied that a mutation had occurred in the kanamycin gene 
resulting in the antibiotic sensitive phenotype. The fourth isolate, F9.80, revealed that no 
vector sequences were retained in its genome when probed with radio labeled pBB l 92C and 
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was further analyzed as a putative aroA mutant Southern blot analysis (Figure 7) comparing 
HindIII-digested genomic DNA of wild-type P. haemoly tica NADC-D 171 to the putative 
aroA mutant F9.80 using radiolabeled STl aroA confirmed earlier Southern blot data 
demonstrating a 2.0 kb increase in molecular size of aroA containing fragment in the mutant 
as compared to wild-type aroA. The increase in size is equal to the ~-lactamase gene 
inserted into the deletion site of aroA. Furthermore, radio labeled plasmid pBB l 92C 
confirmed that no vector sequences were present in the genome of F9.80. Linearized plasmid 
pBB l 92Cl'!..aroA-ampR was used as a control. Finally, the 200 bp Ndel-BstEil aroA deleted 
fragment was radiolabeled and hybridized to wildtype, F9.80 DNAs, and linearized 
pBB l 92Cl'!..aroA-ampR replacement plasmid. The mutant DNA failed to hybridize to the 200 
bp fragment whereas wildtype DNA did so. The events that transpired to produce the aroA 
mutant are depicted in Figure 6. 
To confirm tryptophan auxotrophy, aroA mutant F9.80 was inoculated into Columbia 
broth containing ampicillin and into Wessman defined media with or without tryptophan. 
Growth in the Columbia broth and in the Wessman broth supplemented with tryptophan were 
comparable, but F9.80 failed to grow in Wessman broth lacking tryptophan. This, taken 
together with Southern blot data demonstrated that F9.80 was an aroA mutant. 
Finally, it was important to confirm that F9.80 was P. haemolytica ST2. Therefore, the 
mutant was struck onto blood agar plates containing 5% sheep erythrocytes for observation 
of ~-hemolysis (34). After overnight incubation at 37°C, noticeable clearing had occurred 
under the mucoid colonies showing erythrocyte lysis consistent with P. haemolytica 
morphology. Furthermore, isolates were chosen from these plates for confirmation of 
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Figure 7. Southern hybridization of genomic DNA from the parental P. haemolytica NADC-D 171 ST 2 (lanes I), the aroA mutant 
(lanes 2), and plasmid pBB I 92CDaroA -aml (lanes 3). One microgram of parental and mutant DNA were digested with Hindi II 
whereas 15 ng of plasmid DNA was digested with S(vl to linearize it. (A) Probed with P. haemolytica STI aroA ; (B) probed with 
pBB l 92C; (C) Probed with Ndel and BstEll double digested and isolated 200bp aroA fragment. A slight band in lane 3 of panel 
(C) indicates that the probe may have been contaminated with some vector sequences. 
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serotype. The rapid plate agglutination assay using ST 1 and ST 2 specific antiserum was 
also confirmatory; no agglutination was observed with ST! antiserum, but marked 
agglutination was observed using ST2 antiserum demonstrating that F9.80 was P. 
haemolytica ST2 (36). 
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CONCLUSIONS 
Summary 
Pneumonic pasteurellosis is a devastating disease affecting a wide variety of animals. The 
principal etiologic agents in cattle and sheep are P. haemolytica STl and ST2, respectively. 
To effectively control these pathogens, vaccines that induce a strong immunity to the 
organism are desirable. One attractive means of achieving this goal is through construction of 
attenuated live vaccines. The aromatic amino acid biosynthetic pathway of prokaryotes yields 
the amino acids tyrosine, tryptophan, and phenylalanine. Many pathogenic bacteria defective 
in this pathway have been shown to be attenuated with a diminished ability to replicate in 
vivo. 
In this study we have cloned and sequenced the P. haemolytica ST2 aroA gene and 
demonstrated that it has 99 .1 % identity with P. haemolytica ST 1 aroA. Furthermore, we have 
constructed a P. haemolytica ST2 aroA mutant by allelic exchange and demonstrated it 
required tryptophan for growth in chemically defined media. Previous studies have shown 
that aroA mutants are good attenuated live vaccine candidates (21, 46, 70, 92). A 
combination of ST 1 and S T2 vaccines may cross protect against the other P. haemolytica 
(biotype A) important to disease. 
Future Research 
A combined multivalent vaccine consisting of an aroA mutant of P. haemolytica STl and 
ST2, P. multocida A3, and Haemophilus somnus may provide cattle and sheep protection 
from field infections with the wild-type of the respective organisms better than the existing 
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vaccines. This hypothesis needs to be further investigated in large scale animal studies. We 
will be further testing the P. haemoly tica ST2 aroA mutant in a small scale sheep study to 
determine the efficacy of this mutant as a potential vaccine candidate. 
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APPENDIX A 
WESSMAN DEFINED MINIMAL MEDIA 
For use with Pasteurella haemolytica, P. multocida, and P. ureae. 
Salt solution is mixed in a total volume of 50 ml dH20: 
Citric acid 1.05 g 
~HP04 2.18 g 
FeS04 27.8 mg 
MnS04 1.6 mg 
pH to 6.5 using xN NaOH 
Amino acid solution is mixed in a total volume of 400 ml dH20 
Alanine 290 mg 
Arginine 370 mg 
Aspartic acid 640 mg 
Glutamic acid 2.03 g 
Glycine 180 mg 
Histidine HCl 280 mg 
Isoleucine 550 mg 
Leucine 830 mg 
Lysine HCl 740 mg 
Phenylalanine 450 mg 
Proline 960 mg 
Valine 650 mg 
Threonine 440 mg 
Tyrosine 150 mg 
Mix the Salt solution and the Amino acid solution and re-pH to 7.4 using Na2C03 
Add to the resulting solution: 
Cysteine HCI 0.16 g 
MgS04 2.23 g 
Ca+2 Pantothenate 0.0025 g 
Nicotinamide 0.005 g 
Thiamine HCI 0.0001 g 
pH to 7.4 using Na2C03 and add the following to the resulting solution: 
Galactose 5 g 
Glucose 0.5 g 
Filter sterilize and store at 4°C 
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APPENDIXB 
GENBANK DEPOSIT OF P. HAEMOLYTICA ST2 AROA NUCLEOTIDE AND 
AMINO ACID SEQUENCES. 
LOCUS PHU89948 1579 bp DNA BCT 16 - MAR- 1997 
DEFINITION Pasteurella haemolytica serotype 2 aroA gene , 
complete eds. 
ACCESS I ON U89948 
NI D g1890138 
KEYWORDS 
SOURC E 
ORGANISM 
RE FERENC E 
AUTHORS 
TI TLE 
JOURNAL 
REFERENC E 
AUTHORS 
TITLE 
JOURNAL 
FEATURES 
source 
gene 
CDS 
Pasteurella haemolytica . 
Pasteurella haemolytica 
Eubacteria; Proteobacteria; gamma subdivision; 
Pasteurellaceae; Pasteurella . 
1 (bases 1 to 1579) 
Hellrung , D. J., Tatum ,F. M. and Briggs , R.E. 
Molecular Cloning , Nucleot i de Sequenc i ng , and 
Construction of a Pasteurella haemo l ytica Ser otype 
2 aroA Mutant 
Unpubl i shed 
2 (bases 1 to 1579) 
Hellrung , D.J ., Tatum , F . M. and Briggs , R . E . 
Direct Submission 
Submitted (18-FEB-1997) RDNRU , National Animal 
Disease Center, Agricultural Research Service, 
United States Departmen t of Agriculture , 2300 
Dayton Ave., Ames, IA 50010 , USA 
Location/Qualifiers 
1. .1579 
/organism="Pasteure l la haemo l ytica " 
/strain=" NADC-D171 " 
/serotype="2 " 
/db_xref="taxon:746 " 
160 .. 1458 
/gene="aroA" 
160 .. 1458 
/ gene="aroA" 
/ codon_ start =l 
/ product= "AroA " 
/ db_xref= "PID:g1890139 " 
/transl table=ll 
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/translation="MEKLTLTPISRVEGEINLPGSKSLSNRALLLAALATGTTQVT 
NLLDSDDIRHMLNALKALGVKYELSDDKTVCVVEGIGGAFKVQNGLSLFLGN 
AGTAMRPLAAALCLKGAETAQIILTGEPRMKERPIKHLVDALRQVGAEVQYL 
ENEGYPPLAISNSGLQGGKVQIDGSISSQFLTALLMSAPLAESDMEIEIIGD 
LVSKPYIDITLSMMNDFGITVENRDYKTFLVKGKQGYVAPQGNYLVEGDASS 
ASYFLASGAIKGKVKVTGIGKKSIQGDRLFADVLEKMGAKITWGEDFIQAEQ 
SPLKGVDMDMNHIPDAAMTIATTALFAEGETVIRNIYNWRVKETDRLTAMAT 
ELRKVGAEVEEGEDFIRIQPLALENFQHAE I ETYNDHRMAMCFSLIALSNTE 
VTILDPNCTAKTFPTYFRELEKLSVR" 
BASE COUNT 
ORIGIN 
488 a 301 c 364 g 426 t 
1 gtgattgttc gctcgatagc aggttatgga atgccgaatc atttacgcat tagtatcggt 
61 ttaccgcaag aaaacgagag attttttact gccttattga aagtgttagc ttaacaagcg 
121 gttacctttt atgaaaattt tacaaat tta aagagaaaaa tggaaaaact aactttaacc 
181 ccgatttccc gagtagaagg cgagatcaat ttacctggtt ctaaaagcct gtctaaccga 
241 gccttattat tagccgcctt agccaccggt acgactcaag tgaccaattt attagatagt 
301 gatgatattc gacatatgct caatgcctta aaagcgt tag gcgtgaaata tgagctatcg 
361 gacgataaaa ccgtctgtgt agttgaaggg attggtggag cttttaaggt tcaaaacggc 
421 t tatcactgt ttctcggcaa tgcaggcacg gcaatgcgac cacttgcagc agcattgtgt 
481 ttaaaagggg cggaaacagc tcaaatcatt cttaccggtg agccaagaat gaaagaacgc 
541 ccgattaaac at t tagtcga tgc t ttacgc caagtagggg cagaggtaca gtatttagaa 
60 1 aatgaaggct atccgccgtt agcaattagc aatagcggtt tgcaaggtgg aaaagtgcaa 
661 attgacggct cgatttccag ccaatttcta accgcattgc tgatgtctgc cccattagcg 
721 gaaagcgata tggaaat tga gattatcggt gatctggtat caaaacct ta tattgatat t 
781 accctttcga tgatgaacga ttttggtatt acggttgaaa atcgagatta caaaaccttt 
84 1 ttagt taaag gtaaacaagg ctatgttgct ccacaaggta attatttggt ggagggagat 
90 1 gcctcttctg cctcttattt cttagcctcc ggtgcgatta aaggcaaggt aaaagtaacg 
961 ggcattggta aaaaatcgat ccaaggcgac cgcttgtttg ccgatgtgtt ggaaaaaatg 
102 1 ggggcaaaaa tcacttgggg agaggatttt attcaagccg agcaatcccc gctaaaaggc 
1081 gtagatatgg atatgaatca tattcctgat gcggcaatga cgattgcaac aaccgc t tta 
1141 tttgccgaag gagaaacagt tatccgcaat a tttataact ggcgggtaaa agaaaccgac 
1201 cgcttgacag caatggcaac cgaattgcgt aaagtcgggg cagaggtaga agaaggggaa 
1261 gattttattc ggattcaacc gcttgcgtta gaaaacttcc agcacgctga aattgaaacc 
1321 tataacgatc accgtatggc aatgtgtttt tcattaattg cgttatcgaa tacagaagtg 
1381 acgatcttag atccaaattg taccgctaaa acgttcccga cttactttag ggagttggaa 
1441 aaattatcgg tcagataaaa gtaaaaaagg attcagaaaa ctgaatcctt tttacgtttt 
150 1 attgtggcag actaagccca accgctaagc cgaattctgc agatatccat cacactggcg 
1561 gccgctcgag catgcatct 
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